Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report sent to investors on Wednesday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 0.3 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $7.37 on Wednesday. Brooklyn ImmunoTherapeutics has a 12-month low of $6.66 and a 12-month high of $8.31. The stock has a market cap of $433.55 million, a PE ratio of -3.25 and a beta of 4.61. The company has a 50-day moving average of $1.07 and a two-hundred day moving average of $1.08.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.